Journal of the International Association of Providers of AIDS Care, published by SAGE PUBLICATIONS INC, is a distinguished open-access journal dedicated to the field of HIV/AIDS care and research. Since its inception in 2002, the journal has provided an essential platform for the dissemination of high-quality, peer-reviewed scholarly articles that advance knowledge in exciting areas such as dermatology, immunology, and infectious diseases. With an impact factor that highlights its role in shaping ongoing discourse, the journal boasts a strong reputation, reflected in its Q1 status in Dermatology and consistent ranking in the top tiers for immunology and infectious diseases in the Scopus Ranks. This commitment to excellence ensures that researchers, healthcare professionals, and students have access to the latest advancements and best practices in HIV/AIDS prevention and care. As a pivotal resource in the global health landscape, the journal stands at the forefront of efforts to combat the challenges presented by this ongoing epidemic.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

HIV Medicine is a prestigious journal published by Wiley that stands at the forefront of research in the fields of health policy, infectious diseases, and pharmacology, with a commendable impact factor reflected in its Q1 rankings for 2023. Established in 1999 and set to converge its expertise through 2024, this journal plays a critical role in advancing the understanding and treatment of HIV and related health challenges. It is esteemed for its rigorous peer-review process and its contributions to both clinical and policy-oriented discussions surrounding HIV medicine. With a broad international readership, it serves as a vital resource for researchers, healthcare professionals, and students committed to fighting the global HIV epidemic. Although not open access, its vital insights are indispensable for anyone involved in infectious disease research and healthcare policy. Articles published in HIV Medicine shape global health strategies and influence the future of HIV research, making it a must-read for those dedicated to this crucial field.

HIV Research & Clinical Practice, published by Taylor & Francis Ltd, is an essential open-access journal dedicated to advancing the knowledge and understanding of HIV-related research and clinical practices. With an ISSN of 2578-7489 and E-ISSN 2578-7470, this acclaimed journal is committed to disseminating cutting-edge studies and innovative treatment strategies within the infectious diseases and pharmacology fields, achieving a commendable Q2 ranking in both categories as of 2023. The journal's scope encompasses a broad range of topics from basic science to clinical application, providing a vital platform for researchers, clinicians, and students to exchange insights and foster collaboration. As an open-access publication since 2022, it ensures that high-quality research is accessible to a global audience, encouraging a greater understanding of HIV and its implications for public health. With its base in the United Kingdom and a convergence period from 2019 to 2024, HIV Research & Clinical Practice stands at the forefront of the fight against HIV/AIDS, making significant contributions to the clinical community and beyond.

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

The Journal of the International AIDS Society, published by John Wiley & Sons Ltd, stands as a premier platform for advancing knowledge in the realms of infectious diseases and public health, boasting a strong Q1 ranking in both categories as of 2023. With its open-access format established since 2004, the journal ensures that groundbreaking research on HIV/AIDS and related issues is widely disseminated and easily accessible to a global audience. This commitment to accessibility significantly enhances its impact factor, making it a vital resource for researchers, practitioners, and students alike who are dedicated to improving health outcomes and understanding the complexities of the epidemic. Covering a diverse range of topics from prevention strategies to health policy, the journal supports its readers in staying at the forefront of public health discourse. With its base in the United States and an impressive Scopus ranking placing it within the top tiers of medical publications, the Journal of the International AIDS Society continues to foster collaboration and innovation in the fight against HIV/AIDS.

AIDS REVIEWS, published by Permanyer Publishing, is a distinguished academic journal dedicated to providing comprehensive insights into the field of AIDS research. Since its inception in 2000, the journal has served as a vital platform for disseminating knowledge on various aspects of HIV/AIDS, including prevention, treatment advancements, and socio-medical implications. With a commendable Q3 ranking in both Infectious Diseases and Medicine (miscellaneous), as well as Pharmacology (medical) in 2023, the journal has made significant strides in the academic community, covering relevant topics and emerging trends up to 2024. Although not open access, AIDS REVIEWS continues to attract contributions from leading researchers and professionals, fostering a collaborative environment aimed at improving health outcomes related to AIDS. Located in Barcelona, Spain, this journal is an essential resource for anyone dedicated to advancing their understanding of this global health challenge.

Retrovirology is a prominent open-access journal published by BMC since 2004, dedicated to the field of retroviral research. With a strong focus on advancing knowledge in both infectious diseases and virology, this interdisciplinary journal has achieved a commendable ranking of Q2 in its respective categories as of 2023, reflecting its significant contribution to the scientific community. Hosted in the United Kingdom, Retrovirology serves a global audience of researchers, professionals, and students, making vital research accessible to all without barriers. The journal's emphasis on high-quality peer-reviewed articles supports the dissemination of groundbreaking findings that could shape the future of virology and related fields. With an impressive Scopus ranking, including a percentile of 65th in Medicine: Infectious Diseases, it stands out as a valuable resource for those committed to understanding and combating viral diseases. Retrovirology continues to be an essential platform for innovative research, with its open-access model ensuring that transformational science reaches the widest possible audience.

JAIDS - Journal of Acquired Immune Deficiency Syndromes, is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamics of HIV/AIDS and its broader implications in the fields of infectious diseases and pharmacology. With an esteemed impact factor that places it in the prestigious Q1 category for both Infectious Diseases and Pharmacology (medical) as of 2023, this journal aims to provide a platform for groundbreaking research, clinical findings, and innovative therapies relevant to the management and prevention of HIV/AIDS. The journal's rigorous editorial standards and commitment to advancing knowledge make it an essential resource for researchers, healthcare professionals, and students invested in the global response to AIDS. Although the journal does not currently offer open access options, it remains instrumental in disseminating high-quality research that shapes clinical practices and policy developments in the field.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.